Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Ping-Tee Tan, Mohamed Ismail Abdul Aziz, Fiona Pearce, Wan-Teck Lim, David Bin-Chia Wu, Kwong Ng

ABSTRACT

BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR) mutation. The objective of this study was to evaluate the cost-effectiveness of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive NSCLC in Singapore. METHODS: A partitioned survival model with three health states (progression-free, progressive disease and death) was developed from a healthcare payer perspective. Survival curves from the LUX-Lung 3 trial (afatinib versus pemetrexed-cisplatin chemotherapy) were extrapolated beyond the trial period to estimate the underlying progression-free survival and overall survival parametric distributions. Rates of adverse reactions were also estimated from LUX-Lung 3 while health utilities from overseas were derived from the literature in the absence of local estimates. Direct costs were sourced from public healthcare institutions in Singapore. Incremental cost-effectiveness ratios (ICERs) were calculated over a 5 year time horizon. Deterministic and probabilistic sensitivity analyses and additional scenario analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results. RESULTS: In the base-case analysis, the ICER for afatinib versus pemetrexed-cisplatin was SG$137,648 per quality-adjusted life year (QALY) gained and SG$109,172 per life-year gained. One-way sensitivity analysis showed the ICER was most sensitive to variations in the utility values, the cost of afatinib and time horizon. Scenario analyses showed that even reducing the cost of afatinib by 50% led to a high ICER which was unlikely to represent a cost-effective use of healthcare resources. CONCLUSIONS: Compared with pemetrexed-cisplatin, afatinib is not cost-effective as a first-line treatment for advanced EGFR mutation-positive NSCLC in Singapore. The findings from our study will be useful to inform local healthcare decision-making and resource allocations for NSCLC treatments, together with other considerations such as clinical effectiveness, safety and affordability of TKIs. More... »

PAGES

352

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y

DOI

http://dx.doi.org/10.1186/s12885-018-4223-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101785426

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29587666


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Afatinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Care Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pemetrexed", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Singapore", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tan", 
        "givenName": "Ping-Tee", 
        "id": "sg:person.013437617370.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013437617370.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aziz", 
        "givenName": "Mohamed Ismail Abdul", 
        "id": "sg:person.014456032113.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014456032113.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pearce", 
        "givenName": "Fiona", 
        "id": "sg:person.015630140770.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015630140770.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Centre Singapore", 
          "id": "https://www.grid.ac/institutes/grid.410724.4", 
          "name": [
            "Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lim", 
        "givenName": "Wan-Teck", 
        "id": "sg:person.0736043070.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736043070.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "David Bin-Chia", 
        "id": "sg:person.014462711604.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014462711604.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ministry of Health", 
          "id": "https://www.grid.ac/institutes/grid.415698.7", 
          "name": [
            "Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ng", 
        "givenName": "Kwong", 
        "id": "sg:person.011536243313.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536243313.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/mdu199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001793280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv270", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001810535"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.36.8456", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002674515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e318299243b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004009500"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70393-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004429924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26372", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013460032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.26372", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013460032"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00121-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014173002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds214", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019179559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70184-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019948065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022055849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.4235", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022283608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.4235", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022283608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jval.2015.04.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028072476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu123", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033797914"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71173-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036794393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70375-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036824416"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.1711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036846263"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-11-139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037378478", 
          "https://doi.org/10.1186/1471-2288-11-139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdv276", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043154035"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-6-84", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044187224", 
          "https://doi.org/10.1186/1477-7525-6-84"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70364-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046378249"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)30033-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047011654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2011.05.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047222743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049707999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.41.2056", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051506609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2011.02.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051872458"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053632002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-6687(03)00118-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054621115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0167-6687(03)00118-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054621115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta14suppl2/10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079210843", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.32.15_suppl.8117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111107399"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR) mutation. The objective of this study was to evaluate the cost-effectiveness of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive NSCLC in Singapore.\nMETHODS: A partitioned survival model with three health states (progression-free, progressive disease and death) was developed from a healthcare payer perspective. Survival curves from the LUX-Lung 3 trial (afatinib versus pemetrexed-cisplatin chemotherapy) were extrapolated beyond the trial period to estimate the underlying progression-free survival and overall survival parametric distributions. Rates of adverse reactions were also estimated from LUX-Lung 3 while health utilities from overseas were derived from the literature in the absence of local estimates. Direct costs were sourced from public healthcare institutions in Singapore. Incremental cost-effectiveness ratios (ICERs) were calculated over a 5\u00a0year time horizon. Deterministic and probabilistic sensitivity analyses and additional scenario analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results.\nRESULTS: In the base-case analysis, the ICER for afatinib versus pemetrexed-cisplatin was SG$137,648 per quality-adjusted life year (QALY) gained and SG$109,172 per life-year gained. One-way sensitivity analysis showed the ICER was most sensitive to variations in the utility values, the cost of afatinib and time horizon. Scenario analyses showed that even reducing the cost of afatinib by 50% led to a high ICER which was unlikely to represent a cost-effective use of healthcare resources.\nCONCLUSIONS: Compared with pemetrexed-cisplatin, afatinib is not cost-effective as a first-line treatment for advanced EGFR mutation-positive NSCLC in Singapore. The findings from our study will be useful to inform local healthcare decision-making and resource allocations for NSCLC treatments, together with other considerations such as clinical effectiveness, safety and affordability of TKIs.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-018-4223-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "name": "Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer\u2019s perspective", 
    "pagination": "352", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7ca9e810fb4d50d6d77e4f907a7002bf13aafb90e2377f5eccb4201b3f08b9ab"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29587666"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-018-4223-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101785426"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-018-4223-y", 
      "https://app.dimensions.ai/details/publication/pub.1101785426"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000367_0000000367/records_88247_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-018-4223-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-018-4223-y'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      75 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-018-4223-y schema:about N08de8d31c731465399b54ebd173d0ac3
2 N2ad14942ba804c3fb1b77a5fa2dd8831
3 N2fedb165c2b240378c18d6fc2fa87e85
4 N37d1beb7c26d40729cc04ef311329ebc
5 N4b84543a3a9545c3a35f1c23c06504a5
6 N5cbadf0d7010474cb5f20200966d2f15
7 N67dd18cc607c4e479cc42def371ce08f
8 N75e211c28d5f488385e2846d5d789e92
9 N9d4f191b7ee44e8287e3945b5157f9c2
10 Nb1cc6354b7814c11a2ed7b25781ed89d
11 Nb22dd72e28a84e79b9b577eaf3764ee8
12 Nb6fe586bf32a4561b8d17daf70406230
13 Nc9eb4d92fb934f5284fe5261d87b81cf
14 Nd569102f20fe4f8e84e5907a11f35e9c
15 Nd71e8e1226074daa8ac4a7c2dfe75c63
16 Ndcd2ca9f59f64ccb8fc776026721649e
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N4d84324726e44251879ad79fad5fa813
20 schema:citation sg:pub.10.1186/1471-2288-11-139
21 sg:pub.10.1186/1477-7525-6-84
22 https://app.dimensions.ai/details/publication/pub.1079210843
23 https://doi.org/10.1002/cncr.26372
24 https://doi.org/10.1016/j.ejca.2011.02.013
25 https://doi.org/10.1016/j.jval.2015.04.008
26 https://doi.org/10.1016/j.lungcan.2011.05.022
27 https://doi.org/10.1016/s0167-6687(03)00118-5
28 https://doi.org/10.1016/s1470-2045(09)70364-x
29 https://doi.org/10.1016/s1470-2045(11)70184-x
30 https://doi.org/10.1016/s1470-2045(11)70393-x
31 https://doi.org/10.1016/s1470-2045(14)70375-4
32 https://doi.org/10.1016/s1470-2045(14)71173-8
33 https://doi.org/10.1016/s1470-2045(15)00121-7
34 https://doi.org/10.1016/s1470-2045(16)30033-x
35 https://doi.org/10.1093/annonc/mds214
36 https://doi.org/10.1093/annonc/mdu123
37 https://doi.org/10.1093/annonc/mdu199
38 https://doi.org/10.1093/annonc/mdv270
39 https://doi.org/10.1093/annonc/mdv276
40 https://doi.org/10.1097/jto.0000000000000033
41 https://doi.org/10.1097/jto.0b013e318299243b
42 https://doi.org/10.1158/1078-0432.ccr-12-2934
43 https://doi.org/10.1200/jco.2008.16.1711
44 https://doi.org/10.1200/jco.2010.33.4235
45 https://doi.org/10.1200/jco.2011.36.8456
46 https://doi.org/10.1200/jco.2011.41.2056
47 https://doi.org/10.1200/jco.2012.44.2806
48 https://doi.org/10.1200/jco.2014.32.15_suppl.8117
49 https://doi.org/10.3310/hta14suppl2/10
50 schema:datePublished 2018-12
51 schema:datePublishedReg 2018-12-01
52 schema:description BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR) mutation. The objective of this study was to evaluate the cost-effectiveness of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive NSCLC in Singapore. METHODS: A partitioned survival model with three health states (progression-free, progressive disease and death) was developed from a healthcare payer perspective. Survival curves from the LUX-Lung 3 trial (afatinib versus pemetrexed-cisplatin chemotherapy) were extrapolated beyond the trial period to estimate the underlying progression-free survival and overall survival parametric distributions. Rates of adverse reactions were also estimated from LUX-Lung 3 while health utilities from overseas were derived from the literature in the absence of local estimates. Direct costs were sourced from public healthcare institutions in Singapore. Incremental cost-effectiveness ratios (ICERs) were calculated over a 5 year time horizon. Deterministic and probabilistic sensitivity analyses and additional scenario analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results. RESULTS: In the base-case analysis, the ICER for afatinib versus pemetrexed-cisplatin was SG$137,648 per quality-adjusted life year (QALY) gained and SG$109,172 per life-year gained. One-way sensitivity analysis showed the ICER was most sensitive to variations in the utility values, the cost of afatinib and time horizon. Scenario analyses showed that even reducing the cost of afatinib by 50% led to a high ICER which was unlikely to represent a cost-effective use of healthcare resources. CONCLUSIONS: Compared with pemetrexed-cisplatin, afatinib is not cost-effective as a first-line treatment for advanced EGFR mutation-positive NSCLC in Singapore. The findings from our study will be useful to inform local healthcare decision-making and resource allocations for NSCLC treatments, together with other considerations such as clinical effectiveness, safety and affordability of TKIs.
53 schema:genre research_article
54 schema:inLanguage en
55 schema:isAccessibleForFree true
56 schema:isPartOf N4fba08f9958d472cb8fe796495d3fc23
57 N5c79ab091043418babd03191a660b5a4
58 sg:journal.1024632
59 schema:name Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
60 schema:pagination 352
61 schema:productId N022e510a363546e5bf66cf4bed07a11e
62 N4ae5e8e881aa4f57b638dd09b5a1637f
63 N79e1b6300b5a4afd8c241e39236b252d
64 N9097556deeed48498cfdba789798f464
65 Nf7e79f66611d446795e90948ec2378e4
66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101785426
67 https://doi.org/10.1186/s12885-018-4223-y
68 schema:sdDatePublished 2019-04-11T13:10
69 schema:sdLicense https://scigraph.springernature.com/explorer/license/
70 schema:sdPublisher N1da9186ab46248c7bd35515f7074cce9
71 schema:url https://link.springer.com/10.1186%2Fs12885-018-4223-y
72 sgo:license sg:explorer/license/
73 sgo:sdDataset articles
74 rdf:type schema:ScholarlyArticle
75 N022e510a363546e5bf66cf4bed07a11e schema:name doi
76 schema:value 10.1186/s12885-018-4223-y
77 rdf:type schema:PropertyValue
78 N08de8d31c731465399b54ebd173d0ac3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Carcinoma, Non-Small-Cell Lung
80 rdf:type schema:DefinedTerm
81 N1da9186ab46248c7bd35515f7074cce9 schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 N23972cdb39a94bddb698265ebb97b735 rdf:first sg:person.014456032113.19
84 rdf:rest Nc7ee0170d945408aaba016e86f7bf661
85 N2ad14942ba804c3fb1b77a5fa2dd8831 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Neoplasm Staging
87 rdf:type schema:DefinedTerm
88 N2f904d3fd46341b0badec127a5869cef rdf:first sg:person.014462711604.46
89 rdf:rest Na415ae6633154d64a8412cf67753a587
90 N2fedb165c2b240378c18d6fc2fa87e85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Neoplasm Metastasis
92 rdf:type schema:DefinedTerm
93 N37d1beb7c26d40729cc04ef311329ebc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Cisplatin
95 rdf:type schema:DefinedTerm
96 N4ae5e8e881aa4f57b638dd09b5a1637f schema:name nlm_unique_id
97 schema:value 100967800
98 rdf:type schema:PropertyValue
99 N4b84543a3a9545c3a35f1c23c06504a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Prognosis
101 rdf:type schema:DefinedTerm
102 N4d84324726e44251879ad79fad5fa813 rdf:first sg:person.013437617370.71
103 rdf:rest N23972cdb39a94bddb698265ebb97b735
104 N4fba08f9958d472cb8fe796495d3fc23 schema:volumeNumber 18
105 rdf:type schema:PublicationVolume
106 N5c79ab091043418babd03191a660b5a4 schema:issueNumber 1
107 rdf:type schema:PublicationIssue
108 N5cbadf0d7010474cb5f20200966d2f15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Mutation
110 rdf:type schema:DefinedTerm
111 N67dd18cc607c4e479cc42def371ce08f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Afatinib
113 rdf:type schema:DefinedTerm
114 N75e211c28d5f488385e2846d5d789e92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Humans
116 rdf:type schema:DefinedTerm
117 N79e1b6300b5a4afd8c241e39236b252d schema:name pubmed_id
118 schema:value 29587666
119 rdf:type schema:PropertyValue
120 N9097556deeed48498cfdba789798f464 schema:name readcube_id
121 schema:value 7ca9e810fb4d50d6d77e4f907a7002bf13aafb90e2377f5eccb4201b3f08b9ab
122 rdf:type schema:PropertyValue
123 N9d4f191b7ee44e8287e3945b5157f9c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Cost-Benefit Analysis
125 rdf:type schema:DefinedTerm
126 Na415ae6633154d64a8412cf67753a587 rdf:first sg:person.011536243313.55
127 rdf:rest rdf:nil
128 Nb1cc6354b7814c11a2ed7b25781ed89d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Singapore
130 rdf:type schema:DefinedTerm
131 Nb22dd72e28a84e79b9b577eaf3764ee8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Treatment Outcome
133 rdf:type schema:DefinedTerm
134 Nb5b44a1da9104db9ba491af6e229916a rdf:first sg:person.0736043070.06
135 rdf:rest N2f904d3fd46341b0badec127a5869cef
136 Nb6fe586bf32a4561b8d17daf70406230 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Health Care Costs
138 rdf:type schema:DefinedTerm
139 Nc7ee0170d945408aaba016e86f7bf661 rdf:first sg:person.015630140770.11
140 rdf:rest Nb5b44a1da9104db9ba491af6e229916a
141 Nc9eb4d92fb934f5284fe5261d87b81cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name ErbB Receptors
143 rdf:type schema:DefinedTerm
144 Nd569102f20fe4f8e84e5907a11f35e9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Lung Neoplasms
146 rdf:type schema:DefinedTerm
147 Nd71e8e1226074daa8ac4a7c2dfe75c63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Pemetrexed
149 rdf:type schema:DefinedTerm
150 Ndcd2ca9f59f64ccb8fc776026721649e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Antineoplastic Combined Chemotherapy Protocols
152 rdf:type schema:DefinedTerm
153 Nf7e79f66611d446795e90948ec2378e4 schema:name dimensions_id
154 schema:value pub.1101785426
155 rdf:type schema:PropertyValue
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
160 schema:name Oncology and Carcinogenesis
161 rdf:type schema:DefinedTerm
162 sg:journal.1024632 schema:issn 1471-2407
163 schema:name BMC Cancer
164 rdf:type schema:Periodical
165 sg:person.011536243313.55 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
166 schema:familyName Ng
167 schema:givenName Kwong
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011536243313.55
169 rdf:type schema:Person
170 sg:person.013437617370.71 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
171 schema:familyName Tan
172 schema:givenName Ping-Tee
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013437617370.71
174 rdf:type schema:Person
175 sg:person.014456032113.19 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
176 schema:familyName Aziz
177 schema:givenName Mohamed Ismail Abdul
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014456032113.19
179 rdf:type schema:Person
180 sg:person.014462711604.46 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
181 schema:familyName Wu
182 schema:givenName David Bin-Chia
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014462711604.46
184 rdf:type schema:Person
185 sg:person.015630140770.11 schema:affiliation https://www.grid.ac/institutes/grid.415698.7
186 schema:familyName Pearce
187 schema:givenName Fiona
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015630140770.11
189 rdf:type schema:Person
190 sg:person.0736043070.06 schema:affiliation https://www.grid.ac/institutes/grid.410724.4
191 schema:familyName Lim
192 schema:givenName Wan-Teck
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736043070.06
194 rdf:type schema:Person
195 sg:pub.10.1186/1471-2288-11-139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037378478
196 https://doi.org/10.1186/1471-2288-11-139
197 rdf:type schema:CreativeWork
198 sg:pub.10.1186/1477-7525-6-84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044187224
199 https://doi.org/10.1186/1477-7525-6-84
200 rdf:type schema:CreativeWork
201 https://app.dimensions.ai/details/publication/pub.1079210843 schema:CreativeWork
202 https://doi.org/10.1002/cncr.26372 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013460032
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.ejca.2011.02.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051872458
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/j.jval.2015.04.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028072476
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/j.lungcan.2011.05.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047222743
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/s0167-6687(03)00118-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054621115
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1016/s1470-2045(09)70364-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046378249
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/s1470-2045(11)70184-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019948065
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/s1470-2045(11)70393-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004429924
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s1470-2045(14)70375-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036824416
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/s1470-2045(14)71173-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036794393
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s1470-2045(15)00121-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014173002
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/s1470-2045(16)30033-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047011654
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1093/annonc/mds214 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019179559
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1093/annonc/mdu123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033797914
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1093/annonc/mdu199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001793280
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1093/annonc/mdv270 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001810535
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1093/annonc/mdv276 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043154035
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1097/jto.0000000000000033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049707999
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1097/jto.0b013e318299243b schema:sameAs https://app.dimensions.ai/details/publication/pub.1004009500
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1158/1078-0432.ccr-12-2934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053632002
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2008.16.1711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036846263
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2010.33.4235 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022283608
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2011.36.8456 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002674515
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2011.41.2056 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051506609
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2012.44.2806 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022055849
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2014.32.15_suppl.8117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111107399
253 rdf:type schema:CreativeWork
254 https://doi.org/10.3310/hta14suppl2/10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139213
255 rdf:type schema:CreativeWork
256 https://www.grid.ac/institutes/grid.410724.4 schema:alternateName National Cancer Centre Singapore
257 schema:name Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, 169610, Singapore, Singapore
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.415698.7 schema:alternateName Ministry of Health
260 schema:name Agency for Care Effectiveness, Ministry of Health, Harrower Hall, 14 College Road, 169853, Singapore, Singapore
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...